IBRX vs J · rev $113.3M vs P/E 36, $14.40B cap
Immunitybio Inc (IBRX) versus Jacobs Solutions Inc. (J) — a side-by-side from cached financials, not a winner call.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
Jacobs Solutions Inc. (J) is a engineering & construction company listed on US.
Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.
J does not have a complete income-statement cache yet.
IBRX currently screens at market cap $7.88B. J currently screens at market cap $14.40B and trailing P/E 36.0.
Not investment advice. Open the IBRX and J stock pages for the full models.
Not investment advice.